Endo International PLC

Endo International — Investor Presentation (December 2014)

19 slides from Endo International's investor presentation, Dec 3, 2014

  1. Slide 1: Endo International plc Presentation, December 3, 2014

    Exhibit 99.1 Exhibit Endo Capital December ©2014International Endo Research 99.1 3, 2014 Pharmaceuticals Presentation plc Inc. All rights reserved.

  2. Slide 2: Additional Information

    Additional ADDITIONAL This (“Endo”) documents with HOLDERS ENTIRETY mailed maintained CERTAIN Endo under for 2014. which the solicitation All available. ErecAid®, in 1© 2014 this the SEC trademarks, communication the and Security the was presentation year to Endo SEC inand rules stockholders Auxiliu

  3. Slide 3: Forward-Looking Statements

    Forward “expects,” views, reasonable fully as therein, forward-looking results. This law. different financial 2© 2014 applicable, presentation described expectations Endo Endo could Looking from measures “anticipates,” assumptions Pharmaceuticals assumes with affect non-GAAP instatements contains ma

  4. Slide 4: Discussion

    Discussion Endo’s 3© 2014 Endo Strategy Topics Pharmaceuticals and OperatingInc. Model All Recent rights reserved. Accomplishments Auxilium Update 2014 Financial Guidance Q&A

  5. Slide 5: Who is Endo?

    Who isto Business Roots Originally Management Became Develop, Malvern, Financial Market 4Close dating Endo cap Endo publically 5,000 Overview manufacture, PA Overview aof family-run Focus back buyout International Products ~$11B employees to traded onin 1920 higher market, 1997 pharmaceutical in in

  6. Slide 6: Endo's Strategic Direction

    Endo’s Build Focus Participate Transform Continue Maximize 5@2014aon Strategic leading Endo maximizing our shareholder operating in commitment Pharmaceuticals specialty global Direction model the specialty value areas value totoby offering serving maximize Inc. of adapting healthcare each Allour abo

  7. Slide 7: Endo Operating Model

    Endo Lean, Performance M&A diversified 6© 2014Operating efficient an Endo important organization metrics Pharmaceuticals operating Model component aligned with model with quick Inc. of building shareholder All decision rights&making reserved. growing intereststhe business long term Agnostic on thera

  8. Slide 8: Executing Our Strategy

    Executing Strengthened Implemented Acquisitions Announced Increased Completed Sharpened 7© 2014 Endo strategic Our focus the agreement and Pharmaceuticals atalent Strategy divestiture lean on in-licensing focus and operating near-term toorganization acquire of HealthTronics deals: model Inc. organic

  9. Slide 9: Endo's Strategy Is Playing Out Over Multiple Horizons

    Endo’s Re-base Right-size Improve Divest Focus Optimize Create Launch Rebuild Opportunistically Transform Pursue Expand Provide 8© 2014R&D value non-core bolt-on larger transformational Endo Strategy pipeline ex-U.S. for R&D the Corporate base the for longer-term business on with Pharmaceuticals acq

  10. Slide 10: Progress on Near-Term Strategic Priorities

    Progress Deploying Announced Closed Enhancing Delivering Maximizing Sharpening Focused TOPAS™ Meeting Raising 9© 2014 Endo acquisitions 2014 our on onsystem capital operational double-digit R&D filing agreement Near-Term base financial Pharmaceuticals Revenue business focus NDA toofaccretive, target

  11. Slide 11: Progress on Near-Term Strategic Priorities – U.S. Generics

    Progress Announced Accelerated Launched Meaningful Brand Acquired FDA-approved ©2014 10 reported Endo on rights first Early opportunity Near-Term our Pharmaceuticals generic sales product to expectation Termination Natesto™ ofversion Strategic ~$400M further for U.S. for Testosterone Inc. of expands

  12. Slide 12: Endo to Acquire Auxilium – Transaction Summary

    Endo toEndo Creates Auxilium Synergies Expected ©2014 11 leading Acquire to annual closing inclusive be Pharmaceuticals immediately specialty Auxilium run in of the rate Auxilium’s first synergies healthcare - Transaction accretive quarter Inc. previously All of of company post-close up rights 2015,

  13. Slide 13: Focus on Organic Growth Drivers

    FocusGeneric Expect U.S. Building Maximizing International New On-track Devices Potential ©2014 12 Branded product on Endo toANDA to new Accessing submit return high Pharmaceuticals launches Pharmaceuticals product portfolio NDA value toand organic launches in for launch Fostering current BEMA® reve

  14. Slide 14: 2014 Financial Guidance

    Revenues Measure Reported Adjusted Weighted Initial $2.50B 63% ~$210M 2014 Year-over-year ($3.95) ~$220M ©2014 13 to Financial Guidance View Endo 65% to - $1.36 $2.62B Gross Operating Interest Diluted Effective (GAAP) Average ($3.80) on Pharmaceuticals to low-double mid-to-high Guidance 2/28/2014 $2

  15. Slide 15: Strategic Summary

    Strategic Summary Strong Sustained New Poised ©2014 14 platform YTD to Endo shifted deliver over-performance operating Pharmaceuticals forimplemented strong growth performance shareholder with inInc. over Auxilium multiple All last through value rights 18 quarters over months third reserved. the lea

  16. Slide 16: Questions & Answers

    Questions ©2014 Endo & Answers Pharmaceuticals Inc. All rights reserved.

  17. Slide 17: Appendix

    ©2014 Endo Pharmaceuticals Inc. All rights reserved. Appendix

  18. Slide 18: Reconciliation of Projected GAAP to Adjusted Diluted EPS

    For an Reconciliation Projected Upfront Amortization Charges Interest expected Diluted The Certain Includes Lower ($3.95) Upper ©2014 17 $4.25 ($3.21) $0.08 $7.48 $0.24 $1.35 $1.89 $0.22 ($3.80) company’s End explanation End Endo $0.22 $4.10 of expense adjusted and for all cash GAAP the of of comple

  19. Slide 19: Endo International Capital December

    Endo International Capital December ©2014 Endo Research 3, 2014 Pharmaceuticals Presentation plc Inc. All rights reserved.

Endo International — Investor Presentation (December 2014) on 6ix